Resources
5 Results (showing 1 - 5)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 3/2/2021 (updated 4/5/2024)
As state policymakers confront the substance use disorder (SUD) epidemic, they require a wide range of data – often found in disparate systems – to understand its impact and craft more effective treatment programs and interventions. This report explores best practices and sources for data gathering and describes how states can help communities access and use data to support local efforts.
Posted 3/2/2021 (updated 4/4/2024)
In light of the accelerating and rapidly evolving overdose crisis in the United States (US), new strategies are needed to address the epidemic and to efficiently engage and retain individuals in care for opioid use disorder (OUD). Moreover, there is an increasing need for novel approaches to using health data to identify gaps in the cascade of care for persons with OUD.
Posted 4/26/2023 (updated 3/27/2024)
OMNI Institute, in partnership with the JBS RCORP-TA team, created the Spring 2023 Data Learning Collaborative for all RCORP grant recipients. These sessions built the foundation for data learning, and we dove into data-related topics during each month’s skills-building session.
Posted 11/11/2022 (updated 3/27/2024)
OMNI Institute, in partnership with the JBS RCORP-TA team, created the 2022-2023 RCORP-TA Data Learning Collaborative (LC) for grantees to come together and share knowledge, talk through challenges, and build relationships with one another. This LC will build upon the foundation established in the prior 2022 RCORP-TA Data Learning Collaborative.
Posted 2/16/2022 (updated 3/26/2024)
In the United States, combined stimulant/opioid overdose mortality has risen dramatically over the last decade. These increases may particularly affect non-Hispanic Black and Hispanic populations. We used death certificate data from the US National Center for Health Statistics (2007–2019) to compare state-level trends in overdose mortality due to opioids in combination with 1) cocaine and 2) methamphetamine and other stimulants (MOS) across racial/ethnic groups (non-Hispanic White, non-Hispanic Black, Hispanic, and non-Hispanic Asian American/Pacific Islander).